Key Insights

Highlights

Success Rate

55% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

20.0%

5 terminated out of 25 trials

Success Rate

54.5%

-32.0% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed with results

Key Signals

5 with results55% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (5)
P 1 (6)
P 2 (10)

Trial Status

Completed6
Terminated5
Recruiting4
Active Not Recruiting4
Unknown3
Suspended1

Trial Success Rate

54.5%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07641036Phase 1Recruiting

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

NCT05285358Phase 1Suspended

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT05712356Phase 2Terminated

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT07556835Not Yet Recruiting

Outcomes After Liver and Biliary Resection at a High-Volume Center

NCT04430738Phase 2Active Not Recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT07146646Phase 2Recruiting

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

NCT05194072Phase 1Terminated

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT06715839Not ApplicableRecruiting

Target-specific immunoPET Imaging of Digestive System Carcinoma

NCT02151084Phase 2Active Not Recruiting

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

NCT04853017Phase 1Completed

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT06789224Not ApplicableCompleted

Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device

NCT04740164Not ApplicableCompleted

A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP

NCT04183712Phase 2RecruitingPrimary

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

NCT05009953Phase 2Terminated

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

NCT03201458Phase 2CompletedPrimary

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

NCT05222854Active Not RecruitingPrimary

Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"

NCT05681949Not ApplicableUnknown

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

NCT02333188Phase 1Completed

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02649712Not ApplicableCompleted

Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction

Scroll to load more

Research Network

Activity Timeline